Navigation Links
Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin
Date:9/17/2012

September 17, 2012 (BRONX, NY) The National Heart, Lung, and Blood Institute, part of the National Institutes of Health, has awarded nearly $11 million to Albert Einstein College of Medicine of Yeshiva University to carry out a five-year multi-institutional study of hemoglobin toxicity that may complicate blood transfusions and reduce the effectiveness of blood substitutes. The long-term goals include making blood transfusions safer and more effective and better matching patients with the transfusion strategy best suited to them.

The research is especially important due to the explosion of obesity, diabetes and metabolic syndrome, which increases inflammation in blood vessels and can lead to transfusion complications.

The $10.8 million program project grant will be overseen by the principle investigator, Einstein's Joel Friedman, M.D., Ph.D. , who holds the Young Men's Division Chair in Physiology and is professor of physiology & biophysics and of medicine. The grant will fund research projects at Einstein, Rice University, the University of California, San Diego and the United States Food and Drug Administration (FDA), directed by Dr. Friedman, John Olson, Ph.D., Marcos Intaglietta, Ph.D., and Abdu Alayash, Ph.D., respectively.

The grant focuses on the study of hemoglobin, the protein that gives red blood cells their color. Red cells transport oxygen throughout the body and deliver it to cells. Hemoglobin normally stays inside red blood cells. But under some conditionsincluding sickle cell anemia and transfusions involving stored bloodred cells break open, or lyse, causing substantial amounts of hemoglobin to become acellular (i.e., still in the bloodstream but no longer inside red cells).

Acellular hemoglobin can initiate toxic chemical reactions and processes. This toxicity can trigger or worsen potentially serious inflammation of blood vessels that can complicate blood transfusions and has hampered development of blood substitutes.

The researchers will use the federal grant to determine the mechanisms responsible for making acellular hemoglobin toxic and to develop strategies for preventing, reducing or even reversing toxicity.

Dr. Friedman has brought together teams from Einstein, Rice, UC San Diego and the FDA to take different but complementary research approaches. Dr. Friedman and his Einstein colleagues, including Parimala Nacharaju, Ph.D. , instructor in physiology & biophysics, will study several possible strategies for neutralizing acellular hemoglobin toxicity, including the novel use of nanoparticles that release nitric oxide gas. These particles were developed at Einstein to counteract the role played by acellular hemoglobin in reducing nitric oxide levels.

The Rice/FDA team will evaluate strategies for limiting the toxic consequences of acellular hemoglobin, which include hypertension caused by reduced nitric oxide levels and damage to blood vessel walls caused by harmful chemicals called free radicals. The UC San Diego team, which includes Amy Tsai, Ph.D., and Pedro Cabrales, Ph.D., will conduct animal testing to discover the mechanisms responsible for hemoglobin-based toxicities and develop ways to reduce or eliminate them.


'/>"/>
Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Researchers find our inner reptile hearts
2. Researchers develop rapid method to measure carbon footprints
3. Rockefeller Universitys Pearl Meister Greengard Prize to be awarded to RNA researcher Joan Steitz
4. Researchers reveal a chemo-resistant cancer stem cell as cancers Achilles heel
5. Researchers use banker plants to help battle whitefly pests
6. Researchers find first evidence for a genetic cause for Barretts oesophagus
7. CIRM funds 6 UC San Diego stem cell researchers
8. Rice University researchers optimize photoluminescent probes to study DNA and more
9. Researchers identify biochemical functions for most of the human genome
10. Georgetown Lombardi researcher awarded Provocative Question grant from NCI
11. NIH-funded researchers restore sense of smell in mice using genetic technique
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance for ... a significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based ...
(Date:12/2/2016)...   SurePure, Inc. (OTCQB: SURP) a global ... has concluded an agreement with Tamarack Biotics under which ... to acquire units of the Company,s patented photopurification technology ... Concurrently with the option, SurePure has ... will seek regulatory approvals in the United ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI ... Coil Actuator with a flexure design that ensures high alignment accuracy by preventing ... and is ideally suited where extreme precision is required, such as in medical ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
Breaking Biology Technology: